REGISTERED NUMBER: 04504403 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JULY 2025

FOR

MEDICYS LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

F J R Desbuquois

M W Lyons

SECRETARY:

M Payraudeau

REGISTERED OFFICE:

2nd Floor

Medway Bridge House

1 - 8 Fairmeadow

Maidstone

Kent

ME14 1JP

REGISTERED NUMBER:

04504403 (England and Wales)

ACCOUNTANTS:

Crowe U.K. LLP

2nd Floor

Medway Bridge House

1-8 Fairmeadow

Maidstone

Kent

ME14 1JP

FIXED ASSETS

Tangible assets

4

16,164

21,560

Investments

5

905,432

899,194

921,596

920,754

CURRENT ASSETS

Debtors

6

1,082,709

1,001,772

Investments

7

5,280,160

4,228,505

Cash at bank and in hand

1,945,950

2,274,632

8,308,819

7,504,909

CREDITORS

Amounts falling due within one year

8

528,145

223,393

NET CURRENT ASSETS

7,780,674

7,281,516

TOTAL ASSETS LESS CURRENT LIABILITIES

8,702,270

8,202,270

PROVISIONS FOR LIABILITIES

374,123

270,355

NET ASSETS

8,328,147

7,931,915

CAPITAL AND RESERVES

Called up share capital

100

100

Retained earnings

8,328,047

7,931,815

8,328,147

7,931,915

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 20 April 2026 and were signed on its behalf by:

F J R Desbuquois - Director

1.	STATUTORY INFORMATION

Medicys Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for at least 12 months following the approval of these financial statements. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Preparation of consolidated financial statements

The financial statements contain information about Medicys Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover

Turnover represents revenue earned for services provided to clients. Revenue is recognised as earned when, and to the extent that, the company obtains the right to consideration in exchange for its performance under those contracts. It is measured at the fair value of the right to consideration, which represents amounts chargeable to clients, including recoverable expenses, but excluding Value Added Tax.

Revenue is generally recognised as contract activity progresses so that for incomplete contracts it reflects the partial performance of the contractual obligations. For such contracts the amount of revenue reflects the accrual of the right to consideration by reference to the value of the work performed. Revenue not billed to clients is included in other debtors.

Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation.

Depreciation is recognised so as to write off the cost of assets less their residual values over the useful lives on the following bases:

Fixtures, fittings & equipment 15% reducing balance and 33% straight line

Financial instruments

The company has elected to apply the recognition and measurement provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which debtors and cash and bank balances, are measured at transaction price including transaction costs.

Other financial assets

Other financial assets are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss.

Basic financial liabilities

Basic financial liabilities, including creditors, are recognised at transition price.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 38 (2024 - 34 ) .

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

Cost

At 1 August 2024

142,164

Additions

13,314

Disposals

(26,728

)

At 31 July 2025

128,750

Depreciation

At 1 August 2024

120,604

Charge for year

15,752

Eliminated on disposal

(23,770

)

At 31 July 2025

112,586

Net book value

At 31 July 2025

16,164

At 31 July 2024

21,560

5.	FIXED ASSET INVESTMENTS

Other

investments

£

Cost

At 1 August 2024

899,194

Additions

6,238

At 31 July 2025

905,432

Net book value

At 31 July 2025

905,432

At 31 July 2024

899,194

Fixed asset investments represents holdings of 1,415,034 Ordinary shares and 727,876 A Ordinary shares in Measure Protocol Limited.

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade debtors

901,791

806,248

Amounts owed by group undertakings

-

12,750

Other debtors

180,918

182,774

1,082,709

1,001,772

Other debtors includes an amount of £nil (2024 - £2,160) due to the company from the director.

7.	CURRENT ASSET INVESTMENTS

2025

2024

£

£

Listed investments

5,280,160

4,228,505

Other investments are held in an investment portfolio which is managed by the company's Financial Planners. The investments are included in the financial statements at fair value which was determined by reference to valuations produced by the investment managers.

8.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade creditors

51,112

36,944

Taxation and social security

210,586

123,920

Other creditors

266,447

62,529

528,145

223,393

9.	LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

2025

2024

£

£

Within one year

27,500

30,000

Between one and five years

-

27,500

27,500

57,500

10.	FINANCIAL INSTRUMENTS

The carrying amount of financial assets include financial instruments measured at fair value through the profit or loss of £5,280,160 (2024 - £4,228,505).

11.	OTHER FINANCIAL COMMITMENTS

The company has provided a guarantee in respect of payments due under a lease of the premises occupied by The Conservatory (Central) Limited, a subsidiary undertaking.

12.	RELATED PARTY DISCLOSURES

Transactions were recognised in the period, in respect of the acquisitions of fixed assets for £4,780 (2024 - £nil) and bad and doubtful debts of £45,247 (2024 - £87,400), with entities over which the entity has control, joint control or significant influence.